SCHEMBL2581905

SCHEMBL2581905

CC(C)c1ccc(Cc2ccccc2O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.63
HSPA5 P11021 1/20 0.54
ESRRA P11474 1/20 0.54
SLC5A1 P13866 1/20 0.44
SLC5A2 P31639 1/20 0.44
CYP3A4 P08684 4/20 0.43
CYP2D6 P10635 3/20 0.43
SLC6A2 P23975 3/20 0.43
SLC6A4 P31645 3/20 0.43
SLC6A3 Q01959 3/20 0.43
KCNH2 Q12809 2/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
ALOX5 P09917 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9776607 0.84 KEAP1 (0.86) KEAP1HSPA5CYP3A4CYP2D6MEN1
SCHEMBL30616875 0.84 KEAP1 (0.86) KEAP1HSPA5CYP3A4CYP2D6MEN1
SCHEMBL27403288 0.84 HSPA5 (0.52) KEAP1HSPA5ESRRACYP3A4CYP2D6
SCHEMBL4799003 0.81 KEAP1 (0.63) KEAP1HSPA5BCL2BCL2L1ALOX5
SCHEMBL8706758 0.81 BID (0.45) KEAP1HSPA5ESRRASLC6A4ALOX15
SCHEMBL24203430 0.79 SLC5A1 (0.42) KEAP1ESRRASLC5A1SLC5A2SLC6A4
SCHEMBL31545899 0.79 MEN1 (0.67) KEAP1MEN1KMT2AALOX5TYR
SCHEMBL1539188 0.79 KEAP1 (0.70) KEAP1HSPA5CYP3A4CYP2D6MEN1
SCHEMBL10622742 0.79 KEAP1 (0.70) KEAP1HSPA5CYP3A4CYP2D6MEN1
SCHEMBL560071 0.79 KEAP1 (0.70) KEAP1HSPA5CYP3A4CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111490229-A Electrode and its manufacturing method, electrode element, electrochemical element 株式会社理光 2020-08-04 CN disclosed
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
CN-101010276-B Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same CHUGAI PHARMACEUTICAL CO LTD 2011-01-12 CN disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
CN-101010276-A Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same CHUGAI PHARMACEUTICAL CO LTD (JP) 2007-08-01 CN disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 KEAP1 901/4885HSPA5 2445/4885ESRRA 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.